A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

PHASE2TerminatedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

November 10, 2020

Primary Completion Date

December 14, 2022

Study Completion Date

April 4, 2023

Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
DRUG

GLPG2737

Capsules administered orally

DRUG

Placebo

Matching placebo capsules administered orally

Trial Locations (20)

1105

Amsterdam UMC, Amsterdam

1200

Cliniques Universitaires St. Luc (UCL), Brussels

3000

UZ Leuven, Leuven

6525

Radboud UMC, Nijmegen

9713

UMCG, Groningen

20132

IRCSS Ospedale San Raffaele, Milan

27100

Fondazione Salvatore Maugeri IRCCS, Pavia

28041

Nefrologia Clinica C.P., Madrid

46017

Hospital Universitario Dr. Peset, Valencia

80131

Azienda Ospedaliera Universitaria Federico II, Napoli

Uni Campania L. Vanvitelli, Napoli

656 91

Fakultni nemocnice u sv. Anny v Brne, Brno

500 05

Fakultni nemocnice Hradec Kralove, Hradec Králové

128 08

Vseobecna fakultni nemocnice v Praze, Prague

01307

Uniklinikum Dresden, Dresden

31-559

Specjalistyczne Centrum Medyczne SCM Spółka z o.o., Krakow

92-213

Szpital Kliniczny UM w Lodzi, Lodz

02-758

DaVita Sp. z o.o. Stacja Dializ, Warsaw

08025

Fundacion Puigvert, Barcelona

08907

Hospital Universitari de Bellvitge, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Galapagos NV

INDUSTRY

NCT04578548 - A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Biotech Hunter | Biotech Hunter